Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens
ted.europa.eu
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 5, 2027
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TEN
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tiotropiumbromid ausschließlich in der Dafo Lösung zur Inhalation, ATC R03BB04 f. d. Z. 01.11.25 - 31.10.27
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Allergenextrakt aus Birkenpollen ausschießlich Dafo SUT, ATC V01AA05 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Raltegravir, ATC J05AJ01 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Formoterol, Beclometason, Glycopyrronium, f. d. Z. 01.11.25 - 31.10.26 (zzgl. Verlängerungsoption 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Natriumphenylbutyrat, ATC A16AX03 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Lenograstim, ATC L03AA10 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Clobetasol ausschließlich in der Darreichungsform Schaum, ATC D07AD01 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Glycopyrroniumbromid, ATC R03BB06 für die Zeit 01.11.2025 - 31.10.2026 (zzgl. Verlängerungsoption 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Filgotinib, ATC L04AF04 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Follitropin beta, ATC G03GA06 für die Zeit 01.11.2025 - 31.10.2027
Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-09
ted.europa.eu
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 5, 2027
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TEN
Germany – Pharmaceutical products – Offene Rahmenvereinbarung über Arzneimittelrabatte gemäß § 130a Abs.8 SGB V mit jederzeitiger Beitrittsmöglichkeit, sog. Zulassungsmodell 2025-09
ted.europa.eu
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 5, 2027
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TEN
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-Verfahrens
ted.europa.eu
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TenderProcurement ContractGermanyOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 5, 2027
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
TEN
Lithuania – Crossheads – 31616 Geležinkelio iešmai
ted.europa.eu
Buyer: LTG Kompetencijų centras UAB (PV) | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-09-05
TenderProcurement ContractLithuaniaOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 5, 2027
Buyer: LTG Kompetencijų centras UAB (PV) | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2027-09-05
TEN
Lithuania – Translation services – Vertimo paslaugų užsakymai per CPO LT elektroninį katalogą
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
grants.gov
The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scient...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 7, 2027
The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.
GRA
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
grants.gov
This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accele...
GrantMixedUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 7, 2027
This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 10 years.
GRA
Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)
grants.gov
The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics,...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 7, 2027
The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address increasingly larger data sets.
GRA
Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)
grants.gov
The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities o...
GrantCash GrantUnited StatesOpen
AmountNot provided on the source page. Please check the official source.
DeadlineSep 7, 2027
The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of childrens language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable toolsto further our understanding of childrens language development and/or impairment, and predictors thereof.
No saved opportunities on this page
Use the star icon near an opportunity title to add it to Favorites.
📅 Best viewed on desktop - or rotate your phone to landscape mode.
#
Opportunity
Type
Region / Country
Amount
Deadline
Source
40326
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Octreotid, ATC H01CB02Buyer: AOK Bayern - Die Gesundheitskasse | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-03
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-VerfahrensBuyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Buyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
40331
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Tiotropiumbromid ausschließlich in der Dafo Lösung zur Inhalation, ATC R03BB04 f. d. Z. 01.11.25 - 31.10.27Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Clobetasol ausschließlich in der Darreichungsform Schaum, ATC D07AD01 für die Zeit 01.11.2025 - 31.10.2027Buyer: DAK-Gesundheit | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
Buyer: Deutsche Rentenversicherung Knappschaft-Bahn-See | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
40344
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach §130a Abs.8 SGB V zu verschiedenen Wirkstoff-/en/-kombinationen mit jederzeitiger Abschlussmöglichkeit im Rahmen des sog. Open House-VerfahrensBuyer: AOK Nordost. Die Gesundheitskasse. | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2027-09-05
Tender
Procurement Contract
Germany
Not provided on the source page. Please check the official source.
NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public heal...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The purpose of the NIH Research Conference Grant (R13) is to support high quality conferences that are relevant to the public health and to the scientific mission of the participating Institutes and Centers.
40348
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial inv...
Grant
Mixed
United States
Not provided on the source page. Please check the official source.
This Funding Opportunity Announcement (FOA) solicits applications from research partnerships formed by academic and industrial investigators to accelerate the development and adoption of promising bioengineering tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies. The goal of the program is to support technological innovations that deliver new capabilities which can realize meaningful solutions within 5 10 years.
40349
Investigator Initiated Innovation in Computational Genomics and Data Science (R21 Clinical Trial Not Allowed)The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in comp...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The purpose of this funding opportunity announcement (FOA) is to invite applications for a broad range of research efforts in computational genomics, data science, statistics, and bioinformatics relevant to one or both of basic or clinical genomic science, and broadly applicable to human health and disease. This FOA supports fundamental genomics research developing innovative analytical methodologies and approaches, early-stage development of tools and software, and refinement or hardening of software and tools of high value to the biomedical genomics community. Work supported under this FOA should be enabling for genomics and be generalizable or broadly applicable across diseases and biological systems. All applications should address how the methods would scale to address increasingly larger data sets.
40350
Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualiz...
Grant
Cash Grant
United States
Not provided on the source page. Please check the official source.
The purpose of this notice of funding opportunity (NOFO) is to encourage community-engaged research that broadens the conceptualization of qualities of the environment that can support language development in children and that focuses on the development of novel measures of childrens language development. The overall goal is to build the number of strengths-focused, culturally and linguistically responsive, and generalizable toolsto further our understanding of childrens language development and/or impairment, and predictors thereof.
No saved opportunities on this page. Use the star icon near an opportunity title.
